(+) Lexicon Pharmaceuticals ( LXRX ), which was up more than 4% as it reported positive topline results from its phase 1a study of LX9211, which is in development for the treatment of neuropathic pain.
In other sector news:
(+) Eli Lilly ( LLY ) was up more than 1% after saying that subgroup analyses of its Monarch 2 and 3 trials reinforced the clinical benefit of Verzenio plus endocrine therapy in the treatment of a certain type of breast cancer.
(+) AmpliPhi Biosciences ( APHB ) was marginally higher as it unveiled a tenfold increase in yield from its manufacturing process, the result of ongoing effort to enhance manufacturing efficiencies for AB-SA01, a clinical-stage lead drug product candidate.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.
Go to Appearance > Customize > Subscribe Pop-up to set this up.
Wealth Empire Newsletter
Register now for free updates and alerts
Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.